Damora Therapeutics (DMRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.39
- Estimate
- -$0.37
- Surprise
- -5.4%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Damora Therapeutics (DMRA) reported a wider loss than forecast — diluted EPS of -$0.39 against the -$0.37 estimate (a 5.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates DMRA Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -5.4% surprise compares with a -14.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: DMR-001
- Concentration risk — Counterparty: Paragon Therapeutics (licensor)
- Quality below floor (1.2 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $30.06
- Price target
- $38.86
- Stop
- $27.96
- Upside to target
- +29.3%
- Reward-to-risk
- 2.5:1
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
DMRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.86B
- P/E (fwd)
- -14.0
- 52-week range
- $2.45–$38.33
- Off 52-week high
- 21.6%
- RSI (14)
- 45
- Volume vs avg
- 0.97×
- Score today
- 5.2/10